Tech News, Magazine & Review WordPress Theme 2017
  • Home
  • Supply Chain Updates
  • Global News
  • Contact Us
  • Home
  • Supply Chain Updates
  • Global News
  • Contact Us
No Result
View All Result
No Result
View All Result
Home Supply Chain Updates

Pharmaceutical giant Mundipharma hit with hefty fine over misleading opioid drug information

usscmc by usscmc
December 23, 2019
Pharmaceutical giant Mundipharma hit with hefty fine over misleading opioid drug information
Share on FacebookShare on Twitter

Posted

December 23, 2019 15:34:45

Packets of OxyContin, Targin and Endone.

Photo:

The Therapeutic Goods Association has fined the makers of Targin (centre) for providing misleading information. (ABC News: Hugh Sando)

A pharma giant has been slapped with a hefty fine for misleading doctors about its opioid pain relief products.

Key points:

  • The Therapeutic Goods Administration issued 24 infringement notices to Mundipharma
  • Prescription opioids are responsible for more deaths and poisonings in Australia than heroin
  • Mundipharma says the breach related to a single sentence quoted in several pieces of marketing material

Mundipharma has been fined $302,400 by the Therapeutic Goods Administration for a series of ads it distributed to doctors and other health professionals.

The regulator issued the company with 24 infringement notices over claims relating to nine types of its oxycodone-based drug Targin.

Targin is a slow-release oxycodone medicine that is blended with a second drug called naloxone to relieve some of the constipation that comes with taking an opioid.

Earlier this year, the ABC reported concerns Mundipharma was falsely advertising the purported benefits of their products to general practitioners.

Pain specialist Simon Holliday said in order to promote their drugs, the company had been misrepresenting the position of two major doctors’ groups on how to prescribe medicines to those with chronic pain.

Experts now believe opioids should be avoided when treating chronic pain and there is emerging evidence that, in some cases, the medicines may actually make patients more sensitive to the pain.

 Dr Simon Holliday in his treating rooms

Photo:

GP and pain specialist Simon Holliday raised the Targin issue with regulators. (ABC News: Alison Branley )

The TGA agreed with concerns that the company was falsely advertising, finding that its marketing to GPs was “misleading, imbalanced and otherwise inaccurate”.

A condition of having TGA registration for medicines is that companies abide by an industry code of conduct that is written by Medicines Australia.

The TGA found Mundipharma’s promotional material did not accurately reflect the medical guidelines from the Faculty of Pain Medicine that it had quoted in an attempt to encourage the prescription of its medicine Targin.

“The TGA considers that opioids should not be represented as a core component of the management of chronic non-cancer pain, and the decision to prescribe opioids should be approached with significant caution,” it said in a statement.

Rising concern over opioid misuse

The fines are part of a push by the regulator to crack down on opioid misuse in Australia.

This has included strong restrictions around the sale of codeine products so that they are no longer available over-the-counter.

In a statement, the regulator said prescription opioids were now responsible for more deaths and poisonings in Australian than their illegal counterpart, heroin.

A Mundipharma logo on a medicine box

Photo:

Mundipharma is the Australian arm of pharmaceutical giant Purdue Pharma. (ABC News: Hugh Sando)

“Every day in Australia, nearly 150 hospitalisations and 14 emergency department admissions involve opioid harm, and three people die from drug-induced deaths involving opioid use,” the statement said.

“The TGA is currently implementing a suite of reforms in the area, including the significant tightening of the ‘indications’ (the appropriate circumstance for use) to restrict the use of opioids in chronic non-cancer pain.”

States including Victoria and Tasmania also now have real-time prescribing at pharmacies to crack down on doctor shopping, but a national scheme is yet to be enacted.

Mundipharma is the Australian arm of Purdue Pharma, the United States company behind Oxycontin, which is facing multi-million-dollar legal challenges because of allegedly deceptive marketing practices.

Those practices have been blamed for contributing to the opioid crisis in that country.

Dr Holliday, who raised the Targin issue with regulators, said the fines would amount to little more than a slap on the wrist for the multi-national.

“I think this will come out of their petty cash tin,” he said.

“Now, they’ve actually been pinged for misleading and aggressive advertising, hopefully, this will lead the TGA to reflect on how commercial influences can corrupt excellent health care.

“Companies are not interested in patient outcomes, they’re interested in profits.”

A brochure for Targin pain relief product

Photo:

The misleading information was distributed to Australian GPs by Mundipharma for its Targin pain relief product. (Hugh Sando: ABC News)

Dr Holiday said the only solution was to better fund independent medical education services like the National Prescribing Service.

“All pharmaceutical companies are day-to-day sailing close to the wind. They will push the envelope to get maximum bang for their buck,” he said.

In a statement, a spokesman for Mundipharma said the breaches related to a single sentence quoted in several pieces of marketing material that related to different dosages for the same drug.

“Mundipharma respectfully disagrees with the TGA’s assessment of the statement but respects the important role of the TGA in regulating the pharmaceutical industry along with Medicines Australia,” he said.

“Mundipharma’s intent was to proactively and voluntarily urge caution when healthcare professionals chose to prescribe an opioid and to clarify that this should only be considered in specific circumstances and as part of an overall treatment program.”

The spokesman said the statement was no longer in use, “but we will continue to caution healthcare professionals on best practice in the prescription of opioids”.

“Mundipharma will continue to strengthen its robust processes to ensure strict compliance with the promotional requirements of the Code and the TGA legislation,” he said.

Topics:

pharmaceuticals,

chemicals-and-pharmaceuticals,

industry,

business-economics-and-finance,

health,

drugs-and-substance-abuse,

addictive,

law-crime-and-justice,

australia

usscmc

usscmc

No Result
View All Result

Recent Posts

  • Volkswagen Announces Pricing of 25% Equity Stake Sale in Porsche
  • Can software simplify the supply chain? Ryan Petersen thinks so
  • A strategic approach to cost reduction for banks and fintechs
  • Study examines supply chain issues and opportunities
  • Instacart acquires hyper local grocery e-commerce platform

Recent Comments

  • Top 5 Supply Chain Certifications that are in high demand | Top 5 Certifications on Top 5 Globally Recognized Supply Chain Certifications
  • 3 Best Procurement Certifications that are most valuable | Procurement Newz on Top 5 Globally Recognized Supply Chain Certifications

Archives

  • September 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • September 2019

Categories

  • Global News
  • Supply Chain Updates

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

slot gacor slot slot gacor 2023 slot 2023 slot gacor terbaru slot gacor terpercaya slot gacor slot gacor slot slot gacor 2023 slot 2023 slot gacor terbaru slot gacor terpercaya slot gacor slot gacor slot slot gacor 2023 slot 2023 slot gacor terbaru slot gacor terpercaya slot gacor

Pages

  • Home
  • Terms of Use
  • Privacy Policy
  • Disclaimer
  • Antispam
  • Contact Us

Categories

  • Global News
  • Supply Chain Updates
slot gacor slot slot gacor 2023 slot 2023 slot gacor terbaru slot gacor terpercaya slot gacor slot gacor slot slot gacor 2023 slot 2023 slot gacor terbaru slot gacor terpercaya slot gacor slot gacor slot slot gacor 2023 slot 2023 slot gacor terbaru slot gacor terpercaya slot gacor

Tags

APICS Globally Recognized Supply Chain Certifications IIPMR Certifications International Institute for Procurement and Market Research (IIPMR) ISM Next Level Purchasing Top 5 Supply Chain Certifications top supply chain certifications

Trending

No Content Available
  • Antispam
  • Contact Us
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms of Use

© 2023 www.usscmc.com

No Result
View All Result
  • Home
  • Supply Chain Updates
  • Global News
  • Contact Us

© 2023 www.usscmc.com

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT